The Regulation of the Angiogenic Factor FGF-Binding Protein (FGF-BP) by the APC/beta-Catenin Signaling Pathway in the Progression of Breast Cancer

Abstract

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services. Angiogenic vessel growth in solid tumors is crucial for the survival of the tumor and provides an avenue for the tumor cells to metastasize to distant sites. Breast cancer tumors are also dependent on angiogenesis for survival. Therefore, understanding the underlying mechanisms of the angiogenic process in breast cancer will enhance our knowledge of the carcinogenic process and provide potential therapeutic targets for the treatment of breast cancer. Our lab has previously shown that FGF-BP]. a binding protein for the angiogenic factor FGF-2. is overexpressed in a certain subset of breast cancers. In the current study we have found that FGF-BP1 is also overexpressed in the mammary tumors of the Min/+ mice, a mouse model that expresses high levels of the oncogene beta-catenin. Using in vitro assays we also show that FGF-BP1 is a direct transcriptional target of beta-catenin that may be working through a novel 13bp fragment in the FGF-BP1 promoter.